What Latigo Biotherapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 2 | 2 |
| Sells | 0 | 0 |
| Total trades | 34 | 34 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 51,752,006 | 51,752,006 |
| Disposed | 0 | 0 |
| Net activity | +51,752,006 | +51,752,006 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Foresite Capital Management V, Llc | 10% owner | Aug 10 | Derivative Conversion · C | +296,880 | — | — | 3,414,544 |
| Foresite Capital Management V, Llc | 10% owner | Aug 10 | Derivative Conversion · C | +3,117,664 | — | — | 3,117,664 |
| Foresite Capital Management V, Llc | 10% owner | Aug 10 | Derivative Conversion · C | +195,776 | — | — | 2,203,800 |
| Foresite Capital Management V, Llc | 10% owner | Aug 10 | Open-market buy · P | +140,000 | $18.00 | +$2.52M | 2,008,024 |
| Foresite Capital Management V, Llc | 10% owner | Aug 10 | Derivative Conversion · C | +742,201 | — | — | 1,868,024 |
| Foresite Capital Management V, Llc | 10% owner | Aug 10 | Derivative Conversion · C | +1,125,823 | — | — | 1,125,823 |
| Foresite Capital Management V, Llc | 10% owner | Aug 10 | Derivative Conversion · C | +445,320 | — | — | 3,562,984 |
| Foresite Capital Management V, Llc | 10% owner | Aug 10 | Derivative Conversion · C | +3,117,664 | — | — | 3,117,664 |
| Seidenberg Beth C | Director | Aug 10 | Derivative Conversion · C | +2,066,857 | — | — | 2,094,813 |
| Seidenberg Beth C | Director | Aug 10 | Derivative Conversion · C | +165,519 | — | — | 5,160,847 |
| Seidenberg Beth C | Director | Aug 10 | Derivative Conversion · C | +1,484,401 | — | — | 4,995,328 |
| Seidenberg Beth C | Director | Aug 10 | Derivative Conversion · C | +3,464,072 | — | — | 3,510,927 |
| Seidenberg Beth C | Director | Aug 10 | Derivative Conversion · C | +1,027,635 | — | — | 5,944,009 |
| Seidenberg Beth C | Director | Aug 10 | Derivative Conversion · C | +3,547,842 | — | — | 4,916,374 |
| Seidenberg Beth C | Director | Aug 10 | Derivative Conversion · C | +938,979 | — | — | 1,368,532 |
| Tananbaum James B. | Director | Aug 10 | Derivative Conversion · C | +296,880 | — | — | 3,414,544 |
| Tananbaum James B. | Director | Aug 10 | Derivative Conversion · C | +3,117,664 | — | — | 3,117,664 |
| Tananbaum James B. | Director | Aug 10 | Derivative Conversion · C | +195,776 | — | — | 2,203,800 |
| Tananbaum James B. | Director | Aug 10 | Open-market buy · P | +140,000 | $18.00 | +$2.52M | 2,008,024 |
| Tananbaum James B. | Director | Aug 10 | Derivative Conversion · C | +742,201 | — | — | 1,868,024 |
Loading...
